Compare Novartis AG (NVS) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs State Street SPDR S&P Homebuilders ETF — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while State Street SPDR S&P Homebuilders ETF trades at $94.82 (market cap $1.49B). The key difference: Novartis AG is far larger — about 180.2× State Street SPDR S&P Homebuilders ETF's market cap, and Novartis AG pays a 3.31% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| NVS | XHB | |
|---|---|---|
Market Cap | $268.57B | $1.49B |
Volume | 1,532,573 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $121.36 |
52-Week Low | $121.80 | $94.86 |
Typical Hold Time | 82 Days | 33 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
XHB, the SPDR S&P Homebuilders ETF, trades at $94.99, showing minimal daily change. Technical indicators are predominantly bearish, with moving averages signaling a downtrend and oscillators neutral. The ETF tracks the homebuilding sector, which faces headwinds from high mortgage rates but shows potential from recent housing policy support and institutional interest.
The outlook for XHB is mixed, balancing sector challenges like rising rates against catalysts such as new housing legislation. Investment opportunity hinges on a housing market rebound, while risks include economic sensitivity and rate volatility. Investor sentiment is cautious but attentive to policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
